The Preclinical Evaluation of Fever-Range, Whole Body Hyperthermia as an Adjuvant to Chemotherapy and Cytokine Immunotherapy for the Treatment of Breast Cancer
Abstract
The work outlined in the original grant proposal was designed to develop new breast cancer treatments that combined a current breast cancer chemotherapy (doxorubicin and Doxil) and a cytokine-based immunotherapy (IL-l2 and IL-2) with fever-like whole body hyperthermia (WBH). We have found that the combination of WBH with Doxil does indeed result in a better anti-tumor effect in our SCID mouse human breast tumor xenograft model when compared to Doxil alone. Experiments examining free Doxorubicin are underway. Additional work has shown that free lL-l2 when used in combination with WBH only marginally enhances the anti- tumor response when compared to the IL-l2 alone in our model. We feel that this is due to the lack of T and B cells in the SCID mice that may have inhibited our cytokine immunotherapy protocol. Therefore additional experiments have been executed using a different model (BALE/c mice bearing Colon 26 tumors) while a more appropriate breast cancer model can be developed. Data using this model have been extremely promising when using both free IL-l2 and polylactic acid microsphere encapsulated IL-l2. Overall, the results generated the past year have been promising.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2000
- Accession Number
- ADA383150
Entities
People
- Michele Pritchard
Organizations
- Health Research, Incorporated